Runx2 protein may be treatment target for pulmonary fibrosis

Runx2 protein may be treatment target for pulmonary fibrosis

A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows, suggesting that inhibiting this protein may be an effective strategy for treating the disease. “Our study suggests Runx2 is a potential therapeutic target for preventing or treating pulmonary…

Nerandomilast shows promise for progressive pulmonary fibrosis

Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to top-line data announced by the company. With those results, nerandomilast met the primary endpoint, or goal, of the study,…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums